HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ICCVAM

This article was originally published in The Rose Sheet

Executive Summary

Addendum to the ICCVAM Evaluation of In Vitro Test Methods for Detecting Potential Endocrine Disruptors: Estrogen Receptor and Androgen Receptor Binding and Transcriptional Activation Assays published in a March 16 Federal Register notice includes recommendation by Interagency Coordinating Committee on the Validation of Alternative Methods to replace four substances that are not commercially available or have restricted availability - anastrazole, CGS 18320B, fadrozole and ICI 182,780 - with 4-hydroxyandrostenedione, chrysin, dicofol and raloxifene HCl. ICCVAM published final report containing minimum procedural standards for standardization and validation of in vitro estrogen and androgen receptor binding and transcriptional activation assays in 2003 (1"The Rose Sheet" June 16, 2003, In Brief). Comments on addendum, which also identifies six other substances that could be replaced, are due May 1...

You may also be interested in...



NICEATM

No public comments were received on the "Addendum to the ICCVAM Evaluation of In Vitro Test Methods for Detecting Potential Endocrine Disruptors: Estrogen Receptor and Androgen Receptor Binding and Transcriptional Activation Assays," the National Toxicology Program Interagency Center for the Evaluation of Alternative Toxicological Methods states in a Sept. 28 Federal Register 1notice. The document is available on the NICEATM Web site. NTP had requested comments on the addendum when it was published in a March 16 Federal Register notice. The addendum proposed replacing four substances from a list proposed for validation of the screening methods (2"The Rose Sheet" March 20, 2006, In Brief)...

Endocrine disruptor screening tests

National Toxicology Program's Interagency Center for the Evaluation of Alternative Toxicological Methods makes available final report on Evaluation of In Vitro Test Methods for Detecting Potential Endocrine Disruptors, according to June 3 Federal Register 1notice. Report features ICCVAM's recommendations on minimum procedural standards for standardization and validation of in vitro estrogen and androgen receptor binding and transcriptional activation assays, NICEATM says. Document also includes list of substances, including three phthalates, proposed for validation of the screening methods. In October, NICEATM solicited comments on an expert panel report on the status of in vitro endocrine disruptor methods (2"The Rose Sheet" Oct. 28, 2002, In Brief)...

GermBloc Hand-Sanitizer Class Action Takes Aim At 99.99% Germ-Killing Claim

Like other hand sanitizer manufacturers, WillSpeed Technology claims its GermBloc “kills 99.99% of germs.” Plaintiffs in a proposed class action filed in Massachusetts federal court allege the claim “grossly overstates” the product’s efficacy, deceiving consumers and endangering them with false confidence.

UsernamePublicRestriction

Register

MT125711

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel